An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The company secures funding to push its lead candidate towards US approval.
Readout of the Pivot-006 trial is brought forward by nearly a year.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
